PDF(Pubmed)
Abstract：
Immunotherapy for hematological malignancies is a rapidly advancing field that has gained momentum in recent years, primarily encompassing chimeric antigen receptor T-cell (CAR-T) therapies, immune checkpoint inhibitors, and other modalities. However, its clinical efficacy remains limited, and drug resistance poses a significant challenge. Therefore, novel immunotherapeutic targets and agents need to be identified. Recently, N6-methyladenosine (m6A), the most prevalent RNA epitope modification, has emerged as a pivotal factor in various malignancies. Reportedly, m6A mutations influence the immunological microenvironment of hematological malignancies, leading to immune evasion and compromising the anti-tumor immune response in hematological malignancies. In this review, we comprehensively summarize the roles of the currently identified m6A modifications in various hematological malignancies, with a particular focus on their impact on the immune microenvironment. Additionally, we provide an overview of the research progress made in developing m6A-targeted drugs for hematological tumor therapy, to offer novel clinical insights.
摘要：
恶性血液病的免疫治疗是近年来发展迅速的领域,主要包括嵌合抗原受体T细胞（CAR-T）疗法，免疫检查点抑制剂，和其他方式。然而,其临床疗效仍然有限，和耐药性构成了重大挑战。因此,需要确定新的免疫治疗靶点和药物。最近,N6-甲基腺苷（m6A），最普遍的RNA表位修饰，已经成为各种恶性肿瘤的关键因素。据报道,m6A突变影响血液系统恶性肿瘤的免疫微环境，导致免疫逃避和损害血液系统恶性肿瘤的抗肿瘤免疫反应。在这次审查中,我们全面总结了目前确定的m6A修饰在各种血液恶性肿瘤中的作用，特别关注它们对免疫微环境的影响。此外,我们概述了在开发用于血液肿瘤治疗的m6A靶向药物方面取得的研究进展，提供新的临床见解。
